Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$129.49 +0.7%	$132.34	$110.86 ▼ $141.23	$223.72B	0.69	6.38 million shs	5.77 million shs
JNJ Johnson & Johnson	$193.78 +0.3%	$180.89	$140.68 ▼ $194.48	$465.34B	0.4	8.79 million shs	7.96 million shs
NVS Novartis	$131.78 +0.3%	$126.80	$96.06 ▼ $133.55	$277.64B	0.64	1.58 million shs	1.38 million shs
PFE Pfizer	$24.68 +0.7%	$24.89	$20.92 ▼ $29.22	$139.35B	0.55	61.16 million shs	35.81 million shs
RHHBY Roche	$44.06 -1.9%	$42.06	$34.10 ▼ $45.94	$285.77B	0.47	1.66 million shs	3.36 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.62%	-1.54%	-4.94%	+2.85%	+8.46%
JNJ Johnson & Johnson	+0.27%	+1.52%	+10.12%	+15.41%	+17.36%
NVS Novartis	+0.25%	+1.91%	+7.28%	+12.63%	+12.46%
PFE Pfizer	+0.68%	-0.14%	+2.71%	-1.77%	-15.53%
RHHBY Roche	-1.89%	-2.69%	+5.43%	+9.52%	+11.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$129.49 +0.7%	$132.34	$110.86 ▼ $141.23	$223.72B	0.69	6.38 million shs	5.77 million shs
JNJ Johnson & Johnson	$193.78 +0.3%	$180.89	$140.68 ▼ $194.48	$465.34B	0.4	8.79 million shs	7.96 million shs
NVS Novartis	$131.78 +0.3%	$126.80	$96.06 ▼ $133.55	$277.64B	0.64	1.58 million shs	1.38 million shs
PFE Pfizer	$24.68 +0.7%	$24.89	$20.92 ▼ $29.22	$139.35B	0.55	61.16 million shs	35.81 million shs
RHHBY Roche	$44.06 -1.9%	$42.06	$34.10 ▼ $45.94	$285.77B	0.47	1.66 million shs	3.36 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	+0.62%	-1.54%	-4.94%	+2.85%	+8.46%
JNJ Johnson & Johnson	+0.27%	+1.52%	+10.12%	+15.41%	+17.36%
NVS Novartis	+0.25%	+1.91%	+7.28%	+12.63%	+12.46%
PFE Pfizer	+0.68%	-0.14%	+2.71%	-1.77%	-15.53%
RHHBY Roche	-1.89%	-2.69%	+5.43%	+9.52%	+11.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.91	Moderate Buy	$147.61	13.99% Upside
JNJ Johnson & Johnson	2.75	Moderate Buy	$200.06	3.24% Upside
NVS Novartis	2.10	Hold	$120.33	-8.69% Downside
PFE Pfizer	2.39	Hold	$28.13	13.95% Upside
RHHBY Roche	3.40	Buy	$50.00	13.48% Upside

Current Analyst Ratings Breakdown

Latest JNJ, RHHBY, ABT, PFE, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2025	JNJ Johnson & Johnson	Daiwa Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$203.00
10/17/2025	ABT Abbott Laboratories	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$159.00 ➝ $162.00
10/16/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$142.00 ➝ $146.00
10/16/2025	ABT Abbott Laboratories	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$147.00
10/16/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $146.00
10/16/2025	ABT Abbott Laboratories	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$145.00 ➝ $150.00
10/16/2025	ABT Abbott Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $149.00
10/16/2025	JNJ Johnson & Johnson	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$210.00 ➝ $215.00
10/15/2025	JNJ Johnson & Johnson	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$210.00
10/15/2025	JNJ Johnson & Johnson	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$174.00 ➝ $209.00
10/15/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$190.00

(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$43.11B	5.23	$6.63 per share	19.53	$27.62 per share	4.69
JNJ Johnson & Johnson	$92.15B	5.06	$13.16 per share	14.73	$29.69 per share	6.53
NVS Novartis	$50.32B	5.53	$10.73 per share	12.28	$21.59 per share	6.10
PFE Pfizer	$63.83B	2.20	$4.39 per share	5.62	$15.62 per share	1.58
RHHBY Roche	$68.73B	4.08	$3.24 per share	13.60	$6.46 per share	6.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.23	22.60	2.44	31.88%	17.78%	10.64%	N/A
JNJ Johnson & Johnson	$14.07B	$10.36	18.70	17.50	2.27	27.26%	33.08%	13.30%	N/A
NVS Novartis	$11.94B	$6.87	19.18	14.96	1.82	25.64%	41.08%	16.83%	10/28/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.13	8.15	0.81	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
RHHBY Roche	$9.40B	N/A	0.00	14.69	2.45	N/A	N/A	N/A	N/A

Latest JNJ, RHHBY, ABT, PFE, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/28/2025	Q3 2025	NVS Novartis	$2.28	N/A	N/A	N/A	$13.70 billion	N/A
10/15/2025	Q3 2025	ABT Abbott Laboratories	$1.30	$1.30	N/A	$0.94	$11.40 billion	$11.37 billion
10/14/2025	Q3 2025	JNJ Johnson & Johnson	$2.76	$2.80	+$0.04	$2.12	$23.73 billion	$23.99 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.82%	N/A	29.57%	54 Years
JNJ Johnson & Johnson	$5.20	2.68%	N/A	50.19%	64 Years
NVS Novartis	$2.60	1.97%	N/A	37.85%	N/A
PFE Pfizer	$1.72	6.97%	N/A	91.49%	16 Years
RHHBY Roche	$0.87	1.97%	N/A	N/A	N/A

Latest JNJ, RHHBY, ABT, PFE, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/14/2025	JNJ Johnson & Johnson	quarterly	$1.30	2.72%	11/25/2025	11/25/2025	12/9/2025
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025
9/19/2025	ABT Abbott Laboratories	quarterly	$0.59	1.82%	10/15/2025	10/15/2025	11/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
JNJ Johnson & Johnson	0.50	1.01	0.76
NVS Novartis	0.53	0.82	0.62
PFE Pfizer	0.65	1.16	0.85
RHHBY Roche	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
JNJ Johnson & Johnson	69.55%
NVS Novartis	13.12%
PFE Pfizer	68.36%
RHHBY Roche	N/A

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
JNJ Johnson & Johnson	0.16%
NVS Novartis	0.01%
PFE Pfizer	0.06%
RHHBY Roche	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
RHHBY Roche	103,249	6.36 billion	N/A	Not Optionable

JNJ, RHHBY, ABT, PFE, and NVS Headlines

Recent News About These Companies

Genentech announces FDA approval for Gazyva for active lupus nephritis

October 20 at 4:43 PM | msn.com

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

October 20 at 4:18 AM | finance.yahoo.com

Roche's Gazyva Gets FDA Approval for Lupus Nephritis

October 20 at 2:40 AM | wsj.com

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

October 20 at 2:00 AM | businesswire.com

Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

October 20 at 2:05 AM | globenewswire.com

Genentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

October 20 at 2:05 AM | businesswire.com

FDA approves Roche's Gazyva/Gazyvaro for the treatment of lupus nephritis

October 20 at 2:00 AM | globenewswire.com

Roche announces results from phase III evERA Breast Cancer study

October 19 at 6:16 PM | msn.com

Genentech’s Phase III evERA data showed giredestrant improved PFS survival

October 19 at 6:16 PM | msn.com

Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

October 18 at 2:45 AM | taiwannews.com.twT

Genentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

October 18 at 2:05 AM | businesswire.com

Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

October 18 at 2:00 AM | globenewswire.com

Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2

October 17, 2025 | msn.com

Genentech presents new Phase 3 data for vamikibart

October 17, 2025 | msn.com

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

October 17, 2025 | globenewswire.com

Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

October 17, 2025 | businesswire.com

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

October 17, 2025 | finance.yahoo.com

Roche licenses cancer candidate from China’s Hansoh Pharma

October 17, 2025 | msn.com

CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis

October 17, 2025 | globenewswire.com

Roche announces Direct-to-Patient program for Xofluza

October 16, 2025 | msn.com

Roche Holding AG $RHHBY Shares Purchased by Yousif Capital Management LLC

October 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JNJ, RHHBY, ABT, PFE, and NVS Company Descriptions

Abbott Laboratories NYSE:ABT

$129.49 +0.95 (+0.74%)

Closing price 10/20/2025 03:59 PM Eastern

Extended Trading

$130.08 +0.59 (+0.45%)

As of 06:10 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Johnson & Johnson NYSE:JNJ

$193.78 +0.56 (+0.29%)

Closing price 10/20/2025 03:59 PM Eastern

Extended Trading

$193.08 -0.70 (-0.36%)

As of 06:18 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novartis NYSE:NVS

$131.78 +0.35 (+0.27%)

Closing price 10/20/2025 03:59 PM Eastern

Extended Trading

$131.31 -0.47 (-0.36%)

As of 06:10 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$24.68 +0.17 (+0.70%)

Closing price 10/20/2025 03:59 PM Eastern

Extended Trading

$24.65 -0.03 (-0.11%)

As of 06:20 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Roche OTCMKTS:RHHBY

$44.06 -0.85 (-1.89%)

As of 10/20/2025 04:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, RHHBY, ABT, PFE, and NVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, RHHBY, ABT, PFE, and NVS Earnings

Compare Dividends

Latest JNJ, RHHBY, ABT, PFE, and NVS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, RHHBY, ABT, PFE, and NVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, RHHBY, ABT, PFE, and NVS Company Descriptions

Abbott Laboratories NYSE:ABT

Johnson & Johnson NYSE:JNJ

Novartis NYSE:NVS

Pfizer NYSE:PFE

Roche OTCMKTS:RHHBY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools